Join PER® September 15th for the New York Advanced Practice Collaborative Meeting! Directed toward NP/PAs, this meeting blends presentations on cutting-edge information with panel discussions to enhance learning.

Results From Long Term Tamoxifen Study

Monday, January 19, 2015
Clinical trial data confirmed that tamoxifen reduces the risk of breast cancer in healthy women who are at increased risk of breast cancer; however, long term follow-up data were lacking. International Breast Cancer Intervention-I (IBIS-I) trial investigators in the United Kingdom, Finland, Australia and other countries conducted a randomized controlled trial of premenopausal and postmenopausal women aged 35–70 years who were deemed to be at an increased risk of developing breast cancer. The women were randomly assigned to receive tamoxifen 20 mg daily or a matching placebo for 5 years. The primary endpoint was the occurrence of breast cancer (invasive breast cancer and ductal carcinoma in situ).

Between 4/14/92 and 3/30/01, 7,154 eligible women were recruited from genetics clinics and breast care clinics in eight countries and randomly assigned to the two treatment groups. The median age at enrollment was 50.8 years in each group. After a median follow up of 16 years, 601 breast cancers were reported, with 251 (7%) occurring in the 3,579 women taking tamoxifen and 350 (9.8%) occurring in the 3,575 women in the placebo group. The researchers concluded that tamoxifen offers a very long period of protection after treatment cessation and substantially improves the benefit-to-harm ratio of the drug for breast cancer prevention.

Cuzick J et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.Published Online: 11 December 2014 The Lancet Oncology 2015; 16(1): 67-75. 

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN
Blog Info
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN is an oncology nursing consultant and editor-in-chief of Oncology Nursing News.
Author Bio
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN, is the Editor-in-Chief for OncLive Nursing. She is an oncology nursing consultant and adjunct assistant professor of nursing at Louisiana State Health Sciences Center in New Orleans, LA. She provides continuing nursing education to nurses across the Unites States, is active in several professional nursing organizations, and is intrigued by the many ways nurses use technology to communicate.
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.